Physician profile
David Reindl
NPI 1568447803
$3,525.34
in general payments reported to CMS, 2019-2025
20 companies · $746 in 2025
The $746 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $39.73 · 2021: $334 · 2022: $773 · 2023: $424 · 2024: $630 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,774 · Education: $26.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,773.65 |
| Education | $26.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,373.08 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $591.20 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $425.23 | 2019-2025 | Tremfya |
| Genzyme Corporation | $215.99 | 2022-2025 | |
| Pfizer INC. | $213.22 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $107.40 | 2022-2025 | Rebyota |
| Madrigal Pharmaceuticals | $83.03 | 2025 | Rezdiffra |
| Lilly USA, LLC | $80.87 | 2023-2024 | Omvoh |
| Phathom Pharmaceuticals, INC. | $75.75 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $69.32 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $44.18 | 2022-2023 | Dupixent |
| Merck Sharp & Dohme LLC | $37.14 | 2019 | |
| Intercept Pharmaceuticals, INC. | $32.33 | 2019-2022 | |
| Allergan, INC. | $32.10 | 2019 | |
| Braintree Laboratories, INC. | $31.87 | 2019-2023 | Suflave, Sutab |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $29.15 | 2024 | |
| Celltrion USA INC. | $26.20 | 2023 | Yuflyma |
| Ipsen Biopharmaceuticals, INC | $25.63 | 2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $18.74 | 2021 | |
| Ambu INC. | $12.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Reindl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.